The S&P/ASX 300 Index (ASX: XKO) is edging slightly lower today after most company's wrapped up their earnings season.
During afternoon trade, the ASX 300 is down 0.11% to 7,461 points.
Let's take a look at which ASX companies are sprinting on the ASX 300 chart today.
Clinuvel Pharmaceuticals Limited (ASX: CUV)
The Clinuvel share price is rocketing 16.28% to a multi-year high of $34 following an optimistic broker note.
Multinational investment bank, Jefferies raised its price target for Clinuvel by 27% to a bullish $36.80. It appears its analysts viewed the company's full-year results in a positive light.
Based on the current share price, this implies an upside of around 8.2% for investors.
Blackmores Limited (ASX: BKL)
The Blackmores share price is also pushing ahead on Friday, up 6.65% to $98.21. The health supplements company also received a broker note by Macquarie following the release of its full-year results yesterday.
Analysts at Macquarie added 19% to its outlook on Blackmores, valuing its shares at $87.50 apiece. It's worth noting that this is still a significant downside from the current price, roughly 11%.
Atlas Arteria Group (ASX: ALX)
Another significant mover today is the Atlas Arteria share price, up 6.27% to $6.69. The toll-road developer provided its half-year results yesterday, however, a number of brokers weighed in on the company.
Swiss investment firm, UBS lifted its rating on Atlas Arteria shares by 19% to $6.85. Morgans has a slightly bearish view, adding just 1.7% to $6.44. And lastly, Macquarie improved its assessment by 4.8% to $6.52.
And which ASX companies are heading the other way?
Australian Strategic Materials Ltd (ASX: ASM)
Deep in negative territory, the Australian Strategic Minerals share price is down a sizeable 16.51% to $11.40. Investors are heading for the hills despite no news coming out of the company.
A possible catalyst for the sharp fall could be investors deciding to take profit off the table. The rare earth elements miner's shares have climbed to incredible highs over the past year, up 400%. In August alone, the company's share price rose 72% to hit a record high of $14 apiece.
Integral Diagnostics Ltd (ASX: IDX)
Also being weighed down by investors today is the Integral Diagnostics share price, down 12.96% to $4.70. The company released its full-year results today, highlighting a mostly positive performance.
However, with the ongoing impacts of COVID-19, the group could not provide revenue or profit guidance for FY22.
